Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.30 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2363098 | 0.89 | NPC1 (0.42) | NPC1LMNATSHRNPSR1KDM4E | |
| SCHEMBL29658144 | 0.86 | MEN1 (0.35) | LMNAKDM4ERECQL | |
| SCHEMBL13365059 | 0.84 | LMNA (0.31) | LMNATSHRNPSR1 | |
| SCHEMBL2362986 | 0.80 | LMNA (0.30) | LMNA | |
| SCHEMBL21596454 | 0.80 | NPC1 (0.36) | NPC1 | |
| SCHEMBL2362708 | 0.79 | L3MBTL1 (0.37) | NPC1NPSR1KDM4ETDP1 | |
| SCHEMBL15558079 | 0.77 | — | — | |
| SCHEMBL13365019 | 0.75 | PDE2A (0.33) | — | |
| SCHEMBL16418269 | 0.74 | LMNA (0.33) | NPC1LMNATSHRNPSR1KDM4E | |
| SCHEMBL29922631 | 0.71 | MEN1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2352723-B1 | PESTICIDAL N-ARYL- OR N-HETEROARYL PYRAZOLE CARBOXAMIDE COMPOUNDS | BAYER IP GMBH (DE) | 2016-11-23 | — | — | EP | disclosed |
| EP-2352723-B1 | PESTICIDAL N-ARYL- OR N-HETEROARYL PYRAZOLE CARBOXAMIDE COMPOUNDS | BAYER IP GMBH (DE) | 2016-11-23 | — | — | EP | disclosed |
| US-20150099766-A1 | Novel halogen-substituted compounds | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-09 | — | — | US | disclosed |
| US-20150099766-A1 | Novel halogen-substituted compounds | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-09 | — | — | US | disclosed |
| US-20150099766-A1 | Novel halogen-substituted compounds | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-09 | — | — | US | disclosed |
| US-8946234-B2 | Halogen-substituted compounds | BAYER CROPSCIENCE AG (DE) | 2015-02-03 | — | — | US | disclosed |
| US-8946234-B2 | Halogen-substituted compounds | BAYER CROPSCIENCE AG (DE) | 2015-02-03 | — | — | US | disclosed |
| US-8946234-B2 | Halogen-substituted compounds | BAYER CROPSCIENCE AG (DE) | 2015-02-03 | — | — | US | disclosed |
| US-8937150-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2015-01-20 | — | — | US | disclosed |
| US-20110301181-A1 | halogen-substituted compounds | BAYER CROPSCIENCE AG (DE) | 2011-12-08 | — | — | US | disclosed |
| US-20110301181-A1 | halogen-substituted compounds | BAYER CROPSCIENCE AG (DE) | 2011-12-08 | — | — | US | disclosed |
| US-20110301181-A1 | halogen-substituted compounds | BAYER CROPSCIENCE AG (DE) | 2011-12-08 | — | — | US | disclosed |
| EP-2352723-A2 | HALOGEN-SUBSTITUTED COMPOUNDS USED AS PESTICIDES | Bayer CropScience AG (DE) | 2011-08-10 | — | — | EP | disclosed |
| WO-2010051926-A2 | NEW HALOGEN-SUBSTITUTED BONDS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010051926-A2 | NEW HALOGEN-SUBSTITUTED BONDS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301181-A1 | halogen-substituted compounds | L3MBTL4, QSOX1, L3MBTL3 | NPC1 2312/4885LMNA 209/4885TSHR 130/4885 |
| US-20150099766-A1 | Novel halogen-substituted compounds | L3MBTL4, PRDX4, PRDX1 | NPC1 2168/4885LMNA 626/4885TSHR 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.